BioMarin Pharmaceutical Inc. (BMRN)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
VOXZOGO Revenue	964.19M	926.92M	735.09M
VIMIZIM Revenue	792.86M	792.05M	739.78M
NAGLAZYME Revenue	507.57M	485.40M	479.58M
PALYNZIQ Revenue	458.83M	433.31M	355.05M
BRINEURA Revenue	195.82M	186.40M	169.08M
ALDURAZYME Revenue	183.38M	208.51M	183.89M
KUVAN Revenue	95.68M	99.53M	120.90M
ROCTAVIAN Revenue	30.28M	35.64M	26.07M
Total Net Product Revenue	3.36B	3.17B	2.81B
Royalty and Other Revenue	42.01M	53.49M	44.47M
Revenue (Other)	-30.28M	-35.64M	-26.07M
Revenue (Total)	3.41B	3.22B	2.85B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Royalty and Other Revenue	42.01M	53.49M	44.47M
United States Revenue	1.20B	1.10B	924.81M
Europe Revenue	917.95M	874.33M	829.03M
Latin America Revenue	461.16M	435.48M	378.08M
Rest of World Revenue (Post-Q2 2024)	597.38M	544.47M	493.63M
Revenue (Other)	183.38M	208.51M	183.89M
Revenue (Total)	3.41B	3.22B	2.85B

Data Source: Fiscal.ai Last updated: Aug 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 7, 2026

Data Sources Report a data error